Pharmaceutical - ViiV Healthcare

Filter

Current filters:

ViiV Healthcare

Popular Filters

1 to 25 of 26 results

GlaxoSmithKline’s third-qtr results not as bad as expected

GlaxoSmithKline’s third-qtr results not as bad as expected

22-10-2014

UK pharma giant GlaxoSmithKline has reported a downturn in both sales and profits for the third quarter…

FinancialGlaxoSmithKlinePharmaceuticalThomson ReutersUKViiV Healthcare

EU marketing authorization for ViiV Healthcare HIV drug Triumeq

EU marketing authorization for ViiV Healthcare HIV drug Triumeq

03-09-2014

The European Commission has granted marketing authorization for ViiV Healthcare’s Triumeq (dolutegravir…

Anti-viralsEuropeGlaxoSmithKlinePharmaceuticalRegulationTriumeqViiV Healthcare

ViiV Healthcare gains FDA approval for HIV drug Triumeq

ViiV Healthcare gains FDA approval for HIV drug Triumeq

23-08-2014

The US Food and Drug Administration has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine…

Anti-viralsGlaxoSmithKlinePfizerPharmaceuticalRegulationShionogiTriumeqUSAViiV Healthcare

IQWIG finds added benefit in adult patients for VIIV Healthcare’s Tivicay

27-05-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

Anti-viralsGermanyGlaxoSmithKlinePharmaceuticalPricingRegulationTivicayViiV Healthcare

ViiV Healthcare grants licence to Medicines Patent Pool to improve access to Tivicay

ViiV Healthcare grants licence to Medicines Patent Pool to improve access to Tivicay

02-04-2014

Viiv Healthcare, the HIV/AIDS joint venture of UK pharma giant GlaxoSmithKline, US drugmaker Pfizer and…

Anti-viralsGlobalPharmaceuticalPricingTivicayViiV Healthcare

Viiv Healthcare comes out top in global survey of pharma industry reputations

14-02-2014

An independent global study has recorded the latest impressions of the corporate reputation of the world’s…

AbbVieGlobalPharmaceuticalResearchViiV Healthcare

Putting patients first is a win-win situation

Putting patients first is a win-win situation

07-02-2014

Here's our take on the week's top stories.

Anti-viralsPharmaceuticalTivicayUKViiV Healthcare

IN FOCUS: Viiv Healthcare’s Tivicay offers new HIV treatment option for patients

IN FOCUS: Viiv Healthcare’s Tivicay offers new HIV treatment option for patients

03-02-2014

Global HIV company Viiv Healthcare has launched its first new treatment option for people with HIV today.

Anti-viralsAtriplaInterviewsIsentressPharmaceuticalPrezistaRegulationResearchTivicayUKViiV Healthcare

ViiV Healthcare’s new HIV medicine Tivicay is approved in Europe

21-01-2014

The European Commission has approved Tivicay (dolutegravir) made by Viiv Healthcare for use in combination…

Anti-viralsEuropePharmaceuticalResearchTivicayViiV Healthcare

Tivicay set to become leading HIV treatment by 2016

Tivicay set to become leading HIV treatment by 2016

15-01-2014

Antiretroviral drug Tivicay (dolutegravir) is set to become the leading integrase inhibitor for the treatment…

Anti-viralsAsia-PacificEuropeIsentressJanssenMarkets & MarketingMerck & CoPharmaceuticalPrezistaTivicayUSAViiV Healthcare

ViiV Healthcare’s Tivicay approved in Canada for HIV

04-11-2013

ViiV Healthcare, the HIV/AIDS joint venture set up by UK pharma giant GlaxoSmithKline with US behemoth…

Anti-viralsdolutegravirGlaxoSmithKlineNorth AmericaPfizerPharmaceuticalRegulationShionogiTivicayViiV Healthcare

ViiV Healthcare presents positive Tivicay results from HIV study

13-09-2013

Positive data has been reported from the Phase IIIb/IV FLAMINGO study of Tivicay (dolutegravir) versus…

Anti-viralsNorth AmericaPharmaceuticalResearchTivicayViiV Healthcare

In wake of Tivicay approval, MSF asks, "when will people in developing countries have access?"

13-08-2013

As the US Food and Drug Administration approved the new HIV drug Tivicay (dolutegravir) late Monday (The…

Anti-viralsdolutegravirGlobalHealthcarePharmaceuticalPricingTivicayViiV Healthcare

FDA approves new ViiV Healthcare HIV drug

13-08-2013

The US Food and Drug Administration yesterday (August 12) approved Tivicay (dolutegravir), a new drug…

Anti-viralsdolutegravirGlaxoSmithKlineNorth AmericaPfizerPharmaceuticalRegulationShionogiTivicayViiV Healthcare

Medicines Patent Pool and ViiV Healthcare collaborate to treat pediatric HIV

28-02-2013

The Medicines Patent Pool (MPP) this week announced the launch of a new collaboration with ViiV Healthcare…

AbacavirAnti-viralsGenericsGlobalPatentsPharmaceuticalViiV Healthcare

Sales of antiretroviral agents for HIV will decline slightly over next decade

18-12-2012

Major-market sales of antiretroviral (ARV) agents for HIV will decline slightly over the next decade,…

Anti-viralsBiotechnologydolutegravirGenericsGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRegulationViiV Healthcare

ViiV Healthcare's dolutegravir shows promise in hard-to-treat HIV patients

16-11-2012

ViiV Healthcare, and HIV/AIDS company jointly owned by GlaxoSmithKline (LSE: GSK), Pfizer (NYSE: PFE)…

Anti-viralsdolutegravirGlaxoSmithKlinePfizerPharmaceuticalResearchShionogiViiV Healthcare

Revised terms for ViiV Healthcare and Shionogi HIV partnership

30-10-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) says that Healthcare, its HIV/AIDS joint venture with Pfizer,…

Anti-viralsdolutegravirGlaxoSmithKlineMergers & AcquisitionsPfizerPharmaceuticalShionogiViiV Healthcare

Shionogi-Viiv Healthcare to start regulatory filing of dolutegravir by year-end

08-10-2012

Shionogi-ViiV Healthcare, a joint venture between Japan's Shionogi (TYO: 4507) and ViiV Healthcare, a…

Anti-viralsdolutegravirGlaxoSmithKlinePfizerPharmaceuticalRegulationResearchShionogiShionogi-ViiV HealthcareViiV Healthcare

1 to 25 of 26 results

Back to top